Faruqi & Faruqi, LLP: Investigating Potential Claims Against Geron Corporation
Faruqi & Faruqi, LLP, a renowned securities law firm based in New York City, is currently investigating potential claims against Geron Corporation (Geron or the Company) (NASDAQ: GERN). The investigation comes after a federal securities class action lawsuit was filed against Geron for alleged violations of securities laws.
Investor Alert: Deadline to Seek Lead Plaintiff Status
If you purchased or acquired Geron securities between June 7, 2024, and February 25, 2025, you may be entitled to compensation. Investors who suffered losses are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). The firm reminds investors of the importance of acting promptly, as the deadline to seek the role of lead plaintiff in this class action is May 12, 2025.
Background
Geron is a biotechnology company that focuses on the discovery and development of therapeutics for regenerative medicine. The Company’s lead product candidate is Imetelstat, a potential treatment for myelofibrosis and beta-thalassemia. However, the Company’s stock price experienced a significant decline following the release of clinical trial data for Imetelstat.
Allegations and Concerns
The securities class action lawsuit alleges that Geron and certain of its executives made false and misleading statements regarding the safety and efficacy of Imetelstat. Specifically, the lawsuit alleges that the Company downplayed the risks associated with Imetelstat and overstated its potential benefits.
Impact on Investors
The allegations against Geron could result in significant financial losses for investors. The decline in Geron’s stock price following the release of clinical trial data not only represents a loss of potential gains but also potential losses for those who sold their shares at a lower price than they could have otherwise received.
Impact on the World
The potential implications of this investigation extend beyond just the investors involved. If the allegations are proven true, it could have a negative impact on the biotechnology industry as a whole. It could also potentially discourage investors from investing in biotech companies, which could slow down the development of new treatments and therapies.
Conclusion
Investors who purchased Geron securities between June 7, 2024, and February 25, 2025, and believe they may have suffered losses as a result of the Company’s alleged misrepresentations are encouraged to contact Faruqi & Faruqi partner Josh Wilson directly. The firm is dedicated to fighting for the rights of investors and ensuring that companies are held accountable for their actions. The deadline to seek the role of lead plaintiff in this class action is May 12, 2025. For more information, please visit Faruqi & Faruqi’s website or contact the firm directly.
- Faruqi & Faruqi, LLP is investigating potential claims against Geron Corporation.
- A federal securities class action lawsuit has been filed against Geron.
- The investigation concerns alleged violations of securities laws.
- The deadline to seek the role of lead plaintiff in this class action is May 12, 2025.
- Investors who purchased Geron securities between June 7, 2024, and February 25, 2025, may be entitled to compensation.
- Contact Faruqi & Faruqi partner Josh Wilson for more information.
- The allegations against Geron could result in significant financial losses for investors.
- The potential implications of this investigation extend beyond just the investors involved.
